Drug intelligence / Profile preview

HTL-0022562

Development stage: Discontinued
Lead developer: Biohaven
Modality: Small Molecules
Administration: Subcutaneous

Overview

HTL-0022562 is a novel, potent, and highly selective small molecule antagonist of the calcitonin gene-related peptide (CGRP) receptor. It was discovered by Sosei Heptares (now Nxera Pharma) using structure-based drug design and developed as a potential therapy for CGRP-mediated disorders such as migraine. The compound demonstrated promising preclinical properties and entered Phase 1 clinical trials to assess safety, tolerability, and pharmacokinetics in healthy subjects. Development was later discontinued for migraine[1][4][6].

Other names: UNII-QP50ESO5RAUNII-QP-50ESO5RAUNII-QP 50ESO5RA

Targets

Calcitonin gene-related peptide type 1 receptor

Beyond the preview

Go deeper on HTL-0022562.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HTL-0022562.

Explore the full profile